<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068455</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-915</org_study_id>
    <secondary_id>2016-003729-41</secondary_id>
    <nct_id>NCT03068455</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma</brief_title>
  <acronym>CheckMate 915</acronym>
  <official_title>A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an investigational immunotherapy Nivolumab,&#xD;
      when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the&#xD;
      return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or&#xD;
      stage IV Melanoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free Survival (RFS) - All Randomized Participants</measure>
    <time_frame>From randomization to Primary Completion Date (up to approximately 3 years)</time_frame>
    <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median values based on Kaplan-Meier Estimates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</measure>
    <time_frame>From randomization to Primary Completion Date (up to approximately 3 years)</time_frame>
    <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - All Randomized Participants</measure>
    <time_frame>From randomization to date of death (up to approximately 45 months)</time_frame>
    <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</measure>
    <time_frame>From randomization to date of death (up to approximately 45 months)</time_frame>
    <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression</measure>
    <time_frame>From randomization to Study Completion Date (up to approximately 45 months)</time_frame>
    <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next-Line Therapies - All Randomized Participants</measure>
    <time_frame>From randomization to start of next therapy or second next therapy (up to approximately 45 months)</time_frame>
    <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level &lt; 1%</measure>
    <time_frame>From randomization to start of next therapy or second next therapy (up to approximately 45 months)</time_frame>
    <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Next Therapy to Second Next Therapy - All Randomized Participants</measure>
    <time_frame>From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)</time_frame>
    <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</measure>
    <time_frame>From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)</time_frame>
    <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants</measure>
    <time_frame>From randomization to progression event (up to approximately 45 months)</time_frame>
    <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</measure>
    <time_frame>From randomization to progression event (up to approximately 45 months)</time_frame>
    <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1844</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>nivolumab</arm_group_label>
    <arm_group_label>nivolumab + ipilimumab</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>nivolumab + ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>BMS-734016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Completely surgically resected stage IIIb/c/d or stage IV melanoma within 12 weeks of&#xD;
             participation in study.&#xD;
&#xD;
          -  Must have full activity or, if limited, must be able to walk and carry out activities&#xD;
             such as light house work or office work&#xD;
&#xD;
          -  No prior anti-cancer treatment for melanoma (except surgery for the melanoma lesion(s)&#xD;
             and/or except for adjuvant radiation therapy (RT) after neurosurgical resection for&#xD;
             central nervous system (CNS) lesions)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of uveal melanoma&#xD;
&#xD;
          -  Patients with active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Prior treatment with interferon (if complete &lt; 6 months prior to participation in&#xD;
             study), anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any&#xD;
             other antibody or drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>19123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, S.C.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5848</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Med Ctr</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology And Hematology Care</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Can Cnt</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Melanoma and Skin Cancer Center</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Washington Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41950-610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ijui</city>
        <state>RIO Grande DO SUL</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Florian√≥polis</city>
        <state>Santa Catarina</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14780-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SAO Paulo</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20220-410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika komplexni onkologicke pece</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika onkologie a radioterapie</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatovenerologicka klinika 3. LF UK a FNKV</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatovenerologicka klinika VFN a 1. LF UK</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>LILLE Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De La Timone</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IOV</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tauranga</city>
        <state>BAY OF Plenty</state>
        <zip>3143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dunedin</city>
        <zip>9001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Nowotworow Ukladowych i Uogolnionych</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Of Oncology &quot;Prof.Dr.Alexandru Trestioreanu&quot; Bucha</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Nectarie Oncology Center</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona-barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral. Univ. Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario De Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West Of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Surrey</name>
      <address>
        <city>Sutton.</city>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <results_first_submitted>June 8, 2021</results_first_submitted>
  <results_first_submitted_qc>July 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2021</results_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03068455/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03068455/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1844 participants randomized and 1833 treated. Reasons not treated: 1 disease progression; 2 participants withdrew consent; 1 poor/non-compliance; 4 participants no longer met study criteria; 3 not reported</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Nivo + Ipi</title>
          <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Nivo</title>
          <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="920"/>
                <participants group_id="P2" count="924"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="917"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="917"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="561"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to stop therapy</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Nivo + Ipi</title>
          <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Nivo</title>
          <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="920"/>
            <count group_id="B2" value="924"/>
            <count group_id="B3" value="1844"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="14.6"/>
                    <measurement group_id="B2" value="54.6" spread="13.7"/>
                    <measurement group_id="B3" value="54.2" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="387"/>
                    <measurement group_id="B3" value="792"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                    <measurement group_id="B2" value="537"/>
                    <measurement group_id="B3" value="1052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="735"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="539"/>
                    <measurement group_id="B2" value="526"/>
                    <measurement group_id="B3" value="1065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="907"/>
                    <measurement group_id="B2" value="911"/>
                    <measurement group_id="B3" value="1818"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence-free Survival (RFS) - All Randomized Participants</title>
        <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median values based on Kaplan-Meier Estimates.</description>
        <time_frame>From randomization to Primary Completion Date (up to approximately 3 years)</time_frame>
        <population>All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS) - All Randomized Participants</title>
          <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median values based on Kaplan-Meier Estimates.</description>
          <population>All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="922"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab + Ipilimumab over Nivolumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
        <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
        <time_frame>From randomization to Primary Completion Date (up to approximately 3 years)</time_frame>
        <population>All randomized participants with PD-L1 expression level &lt; 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma. PD-L1 expression levels based on Interactive Response Technology (IRT)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
          <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
          <population>All randomized participants with PD-L1 expression level &lt; 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma. PD-L1 expression levels based on Interactive Response Technology (IRT)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.15" lower_limit="22.21" upper_limit="NA">Upper limit not calculable as upper CI bound does not cross 50% threshold</measurement>
                    <measurement group_id="O2" value="27.63" lower_limit="19.81" upper_limit="NA">Upper limit not calculable as upper CI bound does not cross 50% threshold</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab + Ipilimumab over Nivolumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - All Randomized Participants</title>
        <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
        <time_frame>From randomization to date of death (up to approximately 45 months)</time_frame>
        <population>All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - All Randomized Participants</title>
          <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
          <population>All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="922"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of overall survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of overall survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab + Ipilimumab over Nivolumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
        <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
        <time_frame>From randomization to date of death (up to approximately 45 months)</time_frame>
        <population>All randomized participants with PD-L1 expression level &lt; 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
          <description>OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.</description>
          <population>All randomized participants with PD-L1 expression level &lt; 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="41.72" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of overall survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of overall survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab + Ipilimumab over Nivolumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression</title>
        <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
        <time_frame>From randomization to Study Completion Date (up to approximately 45 months)</time_frame>
        <population>All randomized participants with variable PD-L1 expression levels (see data table for details). PD-L1 expression levels based on clinical database.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS) by Baseline Tumor PD-L1 Expression</title>
          <description>RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.&#xD;
Median based on Kaplan-Meier Estimates.</description>
          <population>All randomized participants with variable PD-L1 expression levels (see data table for details). PD-L1 expression levels based on clinical database.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="920"/>
                <count group_id="O2" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 1% Tumor PD-L1 Expression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="350"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.18" lower_limit="22.21" upper_limit="NA">Upper limit not calculable as upper CI bound does not cross 50% threshold</measurement>
                    <measurement group_id="O2" value="25.33" lower_limit="19.81" upper_limit="NA">Upper limit not calculable as upper CI bound does not cross 50% threshold</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>‚â• 1% Tumor PD-L1 Expression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="527"/>
                    <count group_id="O2" value="534"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>‚â• 5% Tumor PD-L1 Expression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="303"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 5% Tumor PD-L1 Expression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="577"/>
                    <count group_id="O2" value="581"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="31.18" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="27.63" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-quantifiable Tumor PD-L1 Expression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="22.41" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="10.87" upper_limit="NA">Median not reached as Kaplan-Meier plot did not reach 0.5 probability of recurrence-free survival</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&lt; 1% Tumor PD-L1 Expression</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Unstratisfied HR, Nivolumab over Ipilimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&gt;= 1% Tumor PD-L1 Expression</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Unstratisfied HR, Nivolumab over ipilimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&gt;= 5% Tumor PD-L1 Expression</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Unstratisfied HR, Nivolumab over ipilimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&lt; 5% Tumor PD-L1 Expression</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Unstratisfied HR, Nivolumab over ipilimumab</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Non-quantifiable Tumor PD-L1 Expression</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Unstratisfied HR, Nivolumab over ipilimumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next-Line Therapies - All Randomized Participants</title>
        <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date.</description>
        <time_frame>From randomization to start of next therapy or second next therapy (up to approximately 45 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next-Line Therapies - All Randomized Participants</title>
          <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date.</description>
          <population>All randomized participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="920"/>
                <count group_id="O2" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to next therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving next therapy</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving next therapy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to second next therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving second next therapy</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving second next therapy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
        <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date</description>
        <time_frame>From randomization to start of next therapy or second next therapy (up to approximately 45 months)</time_frame>
        <population>All randomized participants with PD-L1 expression level &lt; 1%</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next-Line Therapies - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
          <description>Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.&#xD;
Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date</description>
          <population>All randomized participants with PD-L1 expression level &lt; 1%</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to next therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving next therapy</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving next therapy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to second next therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving second next therapy</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached because of an insufficient number of participants receiving second next therapy</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Next Therapy to Second Next Therapy - All Randomized Participants</title>
        <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
        <time_frame>From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)</time_frame>
        <population>All randomized participants who received first and second next systemic therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Next Therapy to Second Next Therapy - All Randomized Participants</title>
          <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
          <population>All randomized participants who received first and second next systemic therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" lower_limit="0.8" upper_limit="23.7"/>
                    <measurement group_id="O2" value="4.80" lower_limit="0.0" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
        <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
        <time_frame>From start of first next systemic therapy to start of second next systemic therapy (up to approximately 28 months)</time_frame>
        <population>All randomized participants with PD-L1 expression level &lt; 1% who received first and second next therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Next Therapy to Second Next Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
          <description>Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.</description>
          <population>All randomized participants with PD-L1 expression level &lt; 1% who received first and second next therapy</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" lower_limit="0.8" upper_limit="23.7"/>
                    <measurement group_id="O2" value="5.04" lower_limit="0.9" upper_limit="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants</title>
        <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
        <time_frame>From randomization to progression event (up to approximately 45 months)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants</title>
          <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
          <population>All randomized participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="920"/>
                <count group_id="O2" value="924"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as insufficient progression events among participants</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as insufficient progression events among participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
        <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
        <time_frame>From randomization to progression event (up to approximately 45 months)</time_frame>
        <population>All randomized participants with PD-L1 expression level &lt; 1%.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Nivo + Ipi</title>
            <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Nivo</title>
            <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) on Next-line Therapy - All Randomized Participants With PD-L1 Expression Level &lt; 1%</title>
          <description>PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.</description>
          <population>All randomized participants with PD-L1 expression level &lt; 1%.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="351"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median not reached as insufficient progression events among participants</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="35.94" upper_limit="NA">Median not reached as insufficient progression events among participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality was assessed from first dose to study completion date (up to approximately 45 months). Serious Adverse Events and Non Serious Adverse Events above 5% were assessed from first dose to 100 days post last dose (up to approximately 15 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Nivo + Ipi</title>
          <description>Arm A: nivolumab 240 mg IV Q2 weeks plus ipilimumab 1 mg/kg IV Q6 weeks (for 1 year of study drug treatment)</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Nivo</title>
          <description>Arm B: nivolumab 480 mg IV Q4 weeks (for 1 year of study drug treatment) with nivolumab placebo on Weeks 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, &amp; 47 and ipilimumab placebo on Weeks 1, 7, 13, 19, 25, 31, 37, 43, &amp; 49</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="374" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Adrenocorticotropic hormone deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lymphocytic hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Primary adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Thyroiditis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Orbital myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Autoimmune pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Immune-mediated enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Ulcerative gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cholangitis sclerosing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nodular regenerative hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adrenalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Campylobacter colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection reactivation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fournier's gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Picornavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fulminant type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Steroid diabetes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myositis-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Marginal zone lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastases to breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Recurrent cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Autoimmune neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Miller Fisher syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myasthenic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Autoimmune nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diaphragmatic spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Immune-mediated pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Drug reaction with eosinophilia and systemic symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="868" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="844" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="338" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="348" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="339" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="917"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="917"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

